A Comparative Systematic Review and Meta-analysis of Amitriptyline with Propranolol and Flunarizine for the Prophylaxis of Migraine Headache
Abstract
OBJECTIVE
To assess the efficacy and safety of amitriptyline as a prophylactic treatment of migraine in comparison with propranolol and flunarizine.
MATERIALS AND METHODS
PubMed, Google Scholar, Cochrane Database of Clinical Trials, and ClinicalTrials.gov were searched along with gray literature, including internet search. Randomized clinical trials (RCTs), prospective and retrospective studies which included migraine patients were included. Screening and extraction of data were conducted, and the quality of randomized studies was evaluated using the Cochrane Risk of Bias tool. RevMan Web was employed for statistical analysis.
RESULTS
About nine studies (n = 874), including seven randomized and two nonrandomized studies, were deemed suitable for data synthesis and analysis. As compared to propranolol, amitriptyline administration significantly lowered the monthly frequency, duration, and severity score of migraines. No significant differences were noted between amitriptyline and flunarizine groups for monthly migraine frequency and migraine severity. Additionally, there were no significant differences in the incidence of adverse reactions following amitriptyline administration when compared with propranolol and flunarizine.
CONCLUSION
Low-dose amitriptyline is a potent prophylactic treatment option for migraine with respect to frequency, duration, as well as severity of migraine episodes. Its efficacy profile is superior to placebo as well as propranolol and comparable to…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 874 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.